View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Marine Leleux ... (+3)
  • Marine Leleux
  • Maureen Schuller
  • Suvi Platerink Kosonen

Bank Brunch/NIBC and Tier 2 thoughts, covered bond supply

A sale of NIBC could open up some potential for Tier 2 outperformance; Slowdown in Covered bond supply after four weeks of heavy activity

Marine Leleux ... (+3)
  • Marine Leleux
  • Maureen Schuller
  • Suvi Platerink Kosonen

Bank Brunch/NIBC and Tier 2 thoughts, covered bond supply

A sale of NIBC could open up some potential for Tier 2 outperformance; Slowdown in Covered bond supply after four weeks of heavy activity

Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Livio Luyten
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi

Morning Notes : BREB BB, OPTI BB, EXM BB, SOLB BB, WDP BB, DEME BB, JD...

: BREB BB, OPTI BB, EXM BB, SOLB BB, WDP BB, DEME BB, JDEP NA, ENRGY BB

 PRESS RELEASE

Bekaert - Update on the Share Buyback Program and Liquidity Agreement

Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 11 September 2025 to 17 September 2025 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 11 September 2025 to 17 September 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 48 659 shares....

 PRESS RELEASE

Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquid...

Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 11 september 2025 tot 17 september 2025 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 25 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 11 september 2025 tot 17 september 2025, Ke...

 PRESS RELEASE

Bekaert - Mise à jour relative au Programme de Rachat d’Actions et au ...

Bekaert - Mise à jour relative au Programme de Rachat d’Actions et au contrat de liquidité Veuillez trouver en annexe le communiqué de presse disponible en anglais et en néerlandais.  Pièces jointes

 PRESS RELEASE

Bekaert: Publication transparency notification

Bekaert: Publication transparency notification Please find herewith the press release. Attachment

 PRESS RELEASE

Bekaert: Publication notification de transparence

Bekaert: Publication notification de transparence Vous trouvez ci-dessous notre communiqué de presse (seulement disponible en anglais et en néerlandais) Pièces jointes

 PRESS RELEASE

Bekaert: Openbaarmaking transparantiekennisgeving

Bekaert: Openbaarmaking transparantiekennisgeving Gelieve in bijlage het persbericht te vinden. Bijlage

Emira Sagaama ... (+3)
  • Emira Sagaama
  • Hela Zarrouk
  • Oliver Metzger
Konrad Zomer
  • Konrad Zomer
Emira Sagaama ... (+3)
  • Emira Sagaama
  • Hela Zarrouk
  • Oliver Metzger
Konrad Zomer
  • Konrad Zomer
Jacob Mekhael
  • Jacob Mekhael

UCB Galvokimig shows strong responses in atopic dermatitis at EADV 202...

UCB announced new 12-week efficacy and 18-week safety data from the phase 1/2a first-in-patient trial for galvokimig (IL-13, IL-17A and IL-17F antibody) in moderate-to-severe atopic dermatitis, to be presented at EADV 2025. The results showed a 52.6% placebo adjusted response on the primary endpoint of =75% improvement from baseline in Eczema Area and Severity Index (EASI75). We view this as competitive compared to other phase 2 trials in atopic dermatitis, and highlight competitor Dupixent's $ ...

Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Mathijs Geerts Danau
  • Michiel Declercq
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

B&S: Sarabel launches recommended all cash offer; Belgian Telecoms: Digi confirms possible minority stake disposal in Spain; market test for Flanders cooperation agreement due any time; Exor: Great companies outperforming the benchmark; PostNL: Feedback on Capital Markets Day event 2025 - new strategy and ambitions 2028; UCB: Encouraging P2a data for Galvokimig in Atopic Dermatitis; Wolters Kluwer: Accelerating share buyback programme and good start to 2H25

Livio Luyten
  • Livio Luyten

Sofina TikTok deal nears, clearing political overhang on Sofina's larg...

The WSJ reported that ByteDance, parent of TikTok, is nearing a deal to resolve U.S. regulatory concerns. A consortium led by Oracle, Silver Lake, and Andreessen Horowitz are set to control 80% of its U.S. business under a U.S.-China framework. The arrangement also includes an American-dominated board and Oracle handling U.S. user data in Texas, while licensing ByteDance's algorithms. Sofina acquired a minority stake in ByteDance in 2016 through a special purpose vehicle alongside other investor...

Jacob Mekhael ... (+2)
  • Jacob Mekhael
  • Mathijs Geerts Danau

UCB Supportive Bimzelx datasets in HS and PsO at EADV 2025

UCB presented updated results for Bimzelx at EADV 2025, with 3-year data showing sustained and deepening responses in HS and 4-year sustained remission in PsO and potential to reduce risk of disease progression to PsA. We continue to view the datasets as supportive of Bimxelx' potential in those indications, and are reflected in the strong commercial uptake to date. We reiterate our € 214 TP and ACCUMULATE rating.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch